Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 19Sarcoma 4Genitourinary 3

Conditions

Prostatic Neoplasms 5024Carcinoma, Renal Cell 1577Urinary Bladder Neoplasms 1279Kidney Neoplasms 724Breast Neoplasms 643Neoplasms 630Carcinoma, Transitional Cell 488Carcinoma, Non-Small-Cell Lung 469Neoplasm Metastasis 468Melanoma 421Ovarian Neoplasms 401Colorectal Neoplasms 373Lung Neoplasms 333Pancreatic Neoplasms 262Sarcoma 232Stomach Neoplasms 227Uterine Cervical Neoplasms 225Testicular Neoplasms 216Non-Muscle Invasive Bladder Neoplasms 215Head and Neck Neoplasms 192Squamous Cell Carcinoma of Head and Neck 189Colonic Neoplasms 167Carcinoma, Hepatocellular 167Esophageal Neoplasms 165Endometrial Neoplasms 165Wilms Tumor 159Recurrence 131Triple Negative Breast Neoplasms 130Small Cell Lung Carcinoma 127Neuroblastoma 127

Interventions

nintedanib 1brivanib 1ALK1-Fc fusion protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Endometrial Adenocarcinoma × Genitourinary × Clear all
NCT01642082 2018-03-13

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

GOG Foundation

Phase 2 Completed
28 enrolled 9 charts
GenitourinaryGynecologic

Endometrial Adenocarcinoma

NCT00888173 2017-12-06

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

GOG Foundation

Phase 2 Completed
45 enrolled 10 charts
GenitourinaryGynecologic

Endometrial Adenocarcinoma

NCT01225887 2017-10-09

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

GOG Foundation

Phase 2 Completed
37 enrolled 11 charts
GenitourinaryGynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡